Erratum: Inflammatory markers in stable heart failure and their relationship with functional class (International Journal of Cardiology (2008) 129 (388-393) DOI: 10.1016/j.ijcard.2007.07.138);Inflammatory markers in stable heart failure and their relationship with functional class

International Journal of Cardiology

Volumn 129, Issue 3, 2008, Pages 388-393

  Sánchez Lázaro, Ignacio J ^a   Almenar, Luis ^b   Reganon, Edelmiro ^b   Vila, Virtudes ^b   Martínez Dolz, Luis ^b   Martínez Sales, Vicenta ^b   Moro, José ^b   Agüero, Jaime ^b   Ortiz Martínez, Víctor ^b   Salvador, Antonio ^b  

^a Hospital Universitario La Fe ^*  (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Functional class; Heart failure; Inflammatory markers; Ventricular function

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; SIALIC ACID; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYOCARDITIS; PRIORITY JOURNAL; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RADIOGRAPHY;

AGED; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED;

EID: 52949108758     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.01.002     Document Type: Erratum

References (25)

1. Torre-Amione G. Inmune activation in chronic heart failure. Am J Cardiol 96 (2005) 3C-8C
2. Anderson M.R. Prog Pediatr Cardiol 11 (2000) 219-230
3. Allain P., Olivier E., Le Bouil A., et al. Increase of sialic acid concentration in the plasma of patients with coronary disease. Presse Med 25 (1996) 96-98
4. Coppola G., Rizzo M., Abrignani M.G., et al. Fibrinogen as a predictor of mortality after acute myocardial infarction: a forty-two month follow-up study. Ital Heart J 6 (2005) 315-322
5. Lang R., Bierig M., Devereux R., et al. Recommendations for chamber quantification: a report from the Amerian Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European society of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18 (2005) 1440-1463
6. Reganon E., Martínez-Sales V., Vila V., et al. Relationship between fibrinogen protein and fibrinogen function in post-myocardial infarction patients. Thromb Res 105 (2001) 1-7
7. Sola S., Mir M., Rajagoplan S., Helmy T., Tandom N., and Khan R. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail 11 (2005) 607-612
8. Anker S.D., Doehner W., Rauchhaus M., et al. Uric acid and survival in chronic heart failure. Circulation 107 (2003) 1991-1997
9. Farquharson C., Butler R., Hill A., Belch J., and Struthers A. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106 (2002) 221-226
10. Lip G., Lip H., Pearce L.A., Chin B.S.P., Conway D.S.G., and Hart R.G. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvular atrial fibrilation. Heart 91 (2005) 759-763
11. Rodríguez-Reyna T.S., Arrieta O., Castillo-Martínez L., et al. Tumour necrosis factor alpha and troponin T as a predictor of poor prognosis in patients with stable Heart failure. Clin Invest Med 28 (2005) 23-29
12. Yin W.H., Chen J.W., Jen H.L., et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 147 (2004) 931-938
13. Alonso-Martínez J.L., Llorente-Diez B., Echegaray-Agara M., Olaz-Preciado F., Urbieta-Echezarreta M., Gonzalez-Arencibia C., et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J heart Fail 4 (2002) 331-336
14. Arnau Vives M.A., Rueda Soriano J., Martínez Dolz L., et al. Valor pronóstico del fibrinógeno en pacientes ingresados con sospecha de angina inestable o infarto de miocardio sin onda Q. Rev Esp Cardiol 55 (2002) 622-630
15. Cugno M., Mari D., Meroni P.L., et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and succesful heart transplantation. Br J Haematol 126 (2004) 85-92
16. Danesh J., Lewington S., Thompson S.G., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294 (2005) 1789-1809
17. Crook J.R., Goldman J.H., Dalziel M., et al. Increased ventricular sialylation in patients with heart failure secondary to ischemic heart disease. Clin Cardiol 20 (1997) 455-458
18. Smith S., Anderson J., Cannon R., et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease. Circulation 110 (2004) 550-553
19. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 449-511
20. Best L.G., Zhang Y., Lee E.T., et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 112 (2005) 1289-1295
21. Smolen J.S., Han C., van der Heijde, et al. Infliximab treatment maintains employability in patients with early rheumatoid artritis. Arthritis Rheum 54 (2006) 716-722
22. Finckh A., Simard J.F., Durvea J., et al. The effectivness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid artritis: a population-based study. Arthritis Rheum 54 (2006) 54-59
23. Cheng E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Anti-TNF therapy against congestive heart failure. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
24. Kosar F., Aksov Y., Ozguntekin G., Ozerol I., and Varol E. Relationship between cytokines and tumor marker in patients with chronic heart failure. Eur J Heart Fail 8 (2006) 270-274
25. Herrera Garza H., Herrera Garza J.L., Rodríguez González H., Treviño Treviño A., Ibarra Flores M., and Torre Amione G. Importancia del factor de necrosis tumoral-alfa en la patogénesis de la insuficiencia cardíaca. Rev Esp Cardiol 55 (2002) 61-66